Analysis of mechanisms underlying BRMS1 suppression of metastasis.
Introduction of normal, neomycin-tagged human chromosome 11 (neo11) reduces the metastatic capacity of MDA-MB-435 human breast carcinoma cells by 70-90% without affecting tumorigenicity. Differential display comparing MDA-MB-435 and neo11/435 led to the discovery of a human breast carcinoma metastasis suppressor gene, BRMS1, which maps to chromosome 11q13.1-q13.2. Stable transfectants of MDA-MB-435 and MDA-MB-231 breast carcinoma cells with BRMS1 cDNA still form progressively growing, locally invasive tumors when injected in mammary fat pads of athymic mice but exhibit significantly lower metastatic potential (50-90% inhibition) to lungs and regional lymph nodes. To begin elucidating the mechanism(s) of action, we measured the ability of BRMS1 to perturb individual steps of the metastatic cascade modeled in vitro. Consistent differences were not observed for adhesion to extracellular matrix components (laminin, fibronectin, type IV collagen, type I collagen, Matrigel); growth rates in vitro or in vivo; expression of matrix metalloproteinases, heparanase, or invasion. Likewise. BRMS1 expression did not up regulate expression of other metastasis suppressors, such as NM23, Kai1, KiSS1 or E-cadherin. Motility of BRMS1 transfectants was modestly inhibited (30-60%) compared to parental and vector-only transfectants. Ability to grow in soft agar was also decreased in MDA-MB-435 cells by 80-89%, but the decrease for MDA-MB-231 was less (13-15% reduction). Also, transfection and re-expression of BRMS1 restored the ability of human breast carcinoma cells to form functional homotypic gap junctions. Collectively, these data suggest that BRMS1 suppresses metastasis of human breast carcinoma by complex, atypical mechanisms.
Samant
R S
RS
Jake Gittlen Cancer Research Institute, Musculoskeletal Research Laboratory, The Pennsylvania State University College of Medicine, Hershey 17033-2390, USA.
Seraj
M J
MJ
Saunders
M M
MM
Sakamaki
T S
TS
Shevde
L A
LA
Harms
J F
JF
Leonard
T O
TO
Goldberg
S F
SF
Budgeon
L
L
Meehan
W J
WJ
Winter
C R
CR
Christensen
N D
ND
Verderame
M F
MF
Donahue
H J
HJ
Welch
D R
DR
D000818:Animals; D015152:Blotting, Northern; D015139:Blotting, Southern; D017931:DNA Primers / Q000737:chemistry; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000378:metabolism / Q000517:prevention & control* / Q000556:secondary; D008325:Mammary Neoplasms, Experimental / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism; D051379:Mice; D008819:Mice, Nude; D009363:Neoplasm Proteins; D010766:Phosphorylation; D011506:Proteins / Q000502:physiology*; D012333:RNA, Messenger / Q000378:metabolism; D012097:Repressor Proteins; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014162:Transfection; D014407:Tumor Cells, Cultured / Q000378:metabolism
C410024:BRMS1 protein, human; D017931:DNA Primers; D009363:Neoplasm Proteins; D011506:Proteins; D012333:RNA, Messenger; D012097:Repressor Proteins; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9